Pellegriti G, Frasca F, Regalbuto C, Squatrito S and Vigneri R: Worldwide increasing incidence of thyroid cancer: Update on epidemiology and risk factors. J Cancer Epidemiol 2013: 965212, 2013.
Goyal N, Setabutr D, Abdulghani J and Goldenberg D: Molecular and genetic markers of follicular-cell thyroid cancer: Etiology and diagnostic and therapeutic opportunities. Adv Exp Med Biol 779: 309-326, 2013.
Nikiforov YE: Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med 135: 569-577, 2011.
Grogan RH, Mitmaker EJ and Clark OH: The evolution of biomarkers in thyroid cancer-from mass screening to a personalized biosignature. Cancers (Basel) 2: 885-912, 2010.
Cabanillas ME, Patel A, Danysh BP, Dadu R, Kopetz S and Falchook G: BRAF inhibitors: Experience in thyroid cancer and general review of toxicity. Horm Cancer 6: 21-36, 2015.
Kim KB, Cabanillas ME, Lazar AJ, Williams MD, Sanders DL, Ilagan JL, Nolop K, Lee RJ and Sherman SI: Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid 23: 1277-1283, 2013.
Liu Z, Li X, Shi L, Maimaiti Y, Chen T, Li Z, Wang S, Xiong Y, Guo H, He W, et al: Cytokeratin 19, thyroperoxidase, HBME-1 and galectin-3 in evaluation of aggressive behavior of papillary thyroid carcinoma. Int J Clin Exp Med 7: 2304-2308, 2014.
Flanagan JN, Pineda P, Knapp PE, De Las Morenas A, Lee SL and Braverman LE: Expression of cytokeratin 19 in the diagnosis of thyroid papillary carcinoma by quantitative polymerase chain reaction. Endocr Pract 14: 168-174, 2008.
Krzeslak A, Gaj Z, Pomorski L and Lipinska A: Expression of cytokeratin 19 in the cytosolic fraction of thyroid lesions: ELISA and western blot analysis. Mol Med Rep 1: 565-569, 2008.
Sumana BS, Shashidhar S and Shivarudrappa AS: Galectin-3 immunohistochemical expression in thyroid neoplasms. J Clin Diagn Res 9: EC07-EC11, 2015.
Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A, Inohara H, Marandino F, Orlandi F, Nardi F, et al; Thyroid Cancer Study Group: Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 357: 1644-1650, 2001.
Inohara H, Honjo Y, Yoshii T, Akahani S, Yoshida J, Hattori K, Okamoto S, Sawada T, Raz A and Kubo T: Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer 85: 2475-2484, 1999.
Gasbarri A, Martegani MP, Del Prete F, Lucante T, Natali PG and Bartolazzi A: Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. J Clin Oncol 17: 3494-3502, 1999.
Carpi A, Rossi G, Coscio GD, Iervasi G, Nicolini A, Carpi F, Mechanick JI and Bartolazzi A: Galectin-3 detection on largeneedle aspiration biopsy improves preoperative selection of thyroid nodules: A prospective cohort study. Ann Med 42: 70-78, 2010.
Liu Z, Yu P, Xiong Y, Zeng W, Li X, Maiaiti Y, Wang S, Song H, Shi L, Liu C, et al: Significance of CK19, TPO, and HBME-1 expression for diagnosis of papillary thyroid carcinoma. Int J Clin Exp Med 8: 4369-4374, 2015.
Mataraci EA, Ozgüven BY and Kabukçuoglu F: Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions. Pol J Pathol 63: 58-64, 2012.
Schmitt AC, Cohen C and Siddiqui MT: Paired box gene 8, HBME-1, and cytokeratin 19 expression in preoperative fineneedle aspiration of papillary thyroid carcinoma: Diagnostic utility. Cancer Cytopathol 118: 196-202, 2010.
Niedziela M, Maceluch J and Korman E: Galectin-3 is not an universal marker of malignancy in thyroid nodular disease in children and adolescents. J Clin Endocrinol Metab 87: 4411-4415, 2002.
Mehrotra P, Okpokam A, Bouhaidar R, Johnson SJ, Wilson JA, Davies BR and Lennard TWJ: Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Histopathology 45: 493-500, 2004.
Mills LJ, Poller DN and Yiangou C: Galectin-3 is not useful in thyroid FNA. Cytopathology 16: 132-138, 2005.
Park YJ, Kwak SH, Kim DC, Kim H, Choe G, Park DJ, Jang HC, Park SH, Cho BY and Park SY: Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules. J Korean Med Sci 22: 621-628, 2007.
Zhu X, Sun T, Lu H, Zhou X, Lu Y, Cai X and Zhu X: Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma. J Clin Pathol 63: 786-789, 2010.
Barroeta JE, Baloch ZW, Lal P, Pasha TL, Zhang PJ and LiVolsi VA: Diagnostic value of differential expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: An immunohistochemical tissue microarray analysis. Endocr Pathol 17: 225-234, 2006.
Kaltner H and Gabius HJ: A toolbox of lectins for translating the sugar code: The galectin network in phylogenesis and tumors. Histol Histopathol 27: 397-416, 2012.
Cludts S, Decaestecker C, Mahillon V, Chevalier D, Kaltner H, André S, Remmelink M, Leroy X, Gabius HJ and Saussez S: Galectin-8 up-regulation during hypopharyngeal and laryngeal tumor progression and comparison with galectin-1, -3 and -7. Anticancer Res 29: 4933-4940, 2009.
Remmelink M, de Leval L, Decaestecker C, Duray A, Crompot E, Sirtaine N, André S, Kaltner H, Leroy X, Gabius HJ, et al: Quantitative immunohistochemical fingerprinting of adhesion/growth-regulatory galectins in salivary gland tumours: Divergent profiles with diagnostic potential. Histopathology 58: 543-556, 2011.
Dawson H, André S, Karamitopoulou E, Zlobec I and Gabius HJ: The growing galectin network in colon cancer and clinical relevance of cytoplasmic galectin-3 reactivity. Anticancer Res 33: 3053-3059, 2013.
Toegel S, Bieder D, André S, Kayser K, Walzer SM, Hobusch G, Windhager R and Gabius HJ: Human osteoarthritic knee cartilage: Fingerprinting of adhesion/growth-regulatory galectins in vitro and in situ indicates differential upregulation in severe degeneration. Histochem Cell Biol 142: 373-388, 2014.
Saussez S, Decaestecker C, Cludts S, Ernoux P, Chevalier D, Smetana K Jr, André S, Leroy X and Gabius HJ: Adhesion/ growth-regulatory tissue lectin galectin-1 in relation to angiogenesis/ lymphocyte infiltration and prognostic relevance of stromal up-regulation in laryngeal carcinomas. Anticancer Res 29: 59-65, 2009.
Amano M, Eriksson H, Manning JC, Detjen KM, André S, Nishimura S, Lehtiö J and Gabius HJ: Tumour suppressor p16(INK4a) - anoikis-favouring decrease in N/O-glycan/cell surface sialylation by down-regulation of enzymes in sialic acid biosynthesis in tandem in a pancreatic carcinoma model. FEBS J 279: 4062-4080, 2012.
Smetana K Jr, André S, Kaltner H, Kopitz J and Gabius HJ: Context-dependent multifunctionality of galectin-1: A challenge for defining the lectin as therapeutic target. Expert Opin Ther Targets 17: 379-392, 2013.
Chiariotti L, Berlingieri MT, Battaglia C, Benvenuto G, Martelli ML, Salvatore P, Chiappetta G, Bruni CB and Fusco A: Expression of galectin-1 in normal human thyroid gland and in differentiated and poorly differentiated thyroid tumors. Int J Cancer 64: 171-175, 1995.
Xu XC, el-Naggar AK and Lotan R: Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol 147: 815-822, 1995.
Salajegheh A, Dolan-Evans E, Sullivan E, Irani S, Rahman MA, Vosgha H, Gopalan V, Smith RA and Lam AK: The expression profiles of the galectin gene family in primary and metastatic papillary thyroid carcinoma with particular emphasis on galectin-1 and galectin-3 expression. Exp Mol Pathol 96: 212-218, 2014.
Saussez S, Glinoer D, Chantrain G, Pattou F, Carnaille B, André S, Gabius HJ and Laurent G: Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. Thyroid 18: 705-712, 2008.
Kaltner H, Seyrek K, Heck A, Sinowatz F and Gabius HJ: Galectin-1 and galectin-3 in fetal development of bovine respiratory and digestive tracts. Comparison of cell type-specific expression profiles and subcellular localization. Cell Tissue Res 307: 35-46, 2002.
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
Kopitz J, Vértesy S, André S, Fiedler S, Schnölzer M and Gabius HJ: Human chimera-type galectin-3: Defining the critical tail length for high-affinity glycoprotein/cell surface binding and functional competition with galectin-1 in neuroblastoma cell growth regulation. Biochimie 104: 90-99, 2014.
de Matos LL, Del Giglio AB, Matsubayashi CO, de Lima Farah M, Del Giglio A and da Silva Pinhal MA: Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: Systematic review and diagnostic meta-analysis. Diagn Pathol 7: 97, 2012.
Dunderović D, Lipkovski JM, Boričic I, Soldatović I, Božic V, Cvejić D and Tatić S: Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature. Diagn Pathol 10: 196, 2015.
Toegel S, Weinmann D, André S, Walzer SM, Bilban M, Schmidt S, Chiari C, Windhager R, Krall C, Bennani-Baiti IM, et al: Galectin-1 couples glycobiology to inflammation in osteoarthritis through the activation of an NF-κB-regulated gene network. J Immunol 196: 1910-1921, 2016.
Zhu X, Wang K, Zhang K, Xu F, Yin Y, Zhu L and Zhou F: Galectin-1 knockdown in carcinoma-associated fibroblasts inhibits migration and invasion of human MDA-MB-231 breast cancer cells by modulating MMP-9 expression. Acta Biochim Biophys Sin (Shanghai) 48: 462-467, 2016.
Saussez S, Cludts S, Capouillez A, Mortuaire G, Smetana K Jr, Kaltner H, André S, Leroy X, Gabius HJ and Decaestecker C: Identification of matrix metalloproteinase-9 as an independent prognostic marker in laryngeal and hypopharyngeal cancer with opposite correlations to adhesion/growth-regulatory galectins-1 and -7. Int J Oncol 34: 433-439, 2009.
Nucera C, Nehs MA, Mekel M, Zhang X, Hodin R, Lawler J, Nose V and Parangi S: A novel orthotopic mouse model of human anaplastic thyroid carcinoma. Thyroid 19: 1077-1084, 2009.
Sewell W, Reeb A and Lin RY: An orthotopic mouse model of anaplastic thyroid carcinoma. J Vis Exp 74: 2013 doi: 10.3791/50097.
Antonello ZA and Nucera C: Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF. Oncogene 33: 5397-5404, 2014.
Camby I, Belot N, Lefranc F, Sadeghi N, de Launoit Y, Kaltner H, Musette S, Darro F, Danguy A, Salmon I, et al: Galectin-1 modulates human glioblastoma cell migration into the brain through modifications to the actin cytoskeleton and levels of expression of small GTPases. J Neuropathol Exp Neurol 61: 585-596, 2002.
Martínez-Bosch N, Fernández-Barrena MG, Moreno M, Ortiz- Zapater E, Munné-Collado J, Iglesias M, André S, Gabius HJ, Hwang RF, Poirier F, et al: Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedgehog signaling activation. Cancer Res 74: 3512-3524, 2014.
Solís D, Bovin NV, Davis AP, Jiménez-Barbero J, Romero A, Roy R, Smetana K Jr and Gabius HJ: A guide into glycosciences: How chemistry, biochemistry and biology cooperate to crack the sugar code. Biochim Biophys Acta 1850: 186-235, 2015.
